5-Fluorocytosine Antagonizes the Action of Sterol Biosynthesis Inhibitors in Candida Glabrata
Overview
Authors
Affiliations
The concentration-dependent antagonistic interaction between 5-fluorocytosine and a sterol biosynthesis inhibitor (SBI) was studied using intact cells and cell-free extracts of Candida glabrata. 5-Fluorocytosine promoted incorporation of radioactivity into 4-desmethylsterols (P < 0.01), and enhanced the relative and absolute increases of ergosterol (P < 0.05) in C. glabrata incubated aerobically with an SBI (miconazole or amorolfine). Further aerobic incubation of C. glabrata with combinations of a nucleic acid or protein synthesis inhibitor (rifampicin or chlortetracycline) and an SBI (miconazole) promoted a similar increase in ergosterol biosynthesis. In contrast, 5-fluorocytosine reduced the incorporation of radioactivity into 4,4-dimethylsterols (P < 0.01), but had no obvious effect on the absolute ergosterol level in C. glabrata incubated statically with miconazole. In cell-free extracts of cultures previously incubated with 5-fluorocytosine, ergosterol synthesis was less sensitive to the action of miconazole. Antagonism between 5-fluorocytosine and the SBI is thus mediated by a reversal of inhibition of intracellular ergosterol synthesis. The possible mechanisms underlying antagonism between 5-fluorocytosine and SBIs that inhibit different sites of the sterol biosynthesis pathway, as well as its clinical relevance to combination therapy, are discussed.
Raman Study of Pathogenic : Imaging Metabolic Machineries in Reaction to Antifungal Drugs.
Pezzotti G, Kobara M, Nakaya T, Imamura H, Asai T, Miyamoto N Front Microbiol. 2022; 13:896359.
PMID: 35694304 PMC: 9175029. DOI: 10.3389/fmicb.2022.896359.
Ogunshe A, Adepoju A, Oladimeji M J Pharm Bioallied Sci. 2011; 3(1):158-64.
PMID: 21430967 PMC: 3053515. DOI: 10.4103/0975-7406.76501.
Mutational analysis of flucytosine resistance in Candida glabrata.
Edlind T, Katiyar S Antimicrob Agents Chemother. 2010; 54(11):4733-8.
PMID: 20823283 PMC: 2976130. DOI: 10.1128/AAC.00605-10.
Antifungal combination therapy: clinical potential.
Baddley J, Pappas P Drugs. 2005; 65(11):1461-80.
PMID: 16033288 DOI: 10.2165/00003495-200565110-00002.
Dannaoui E, Lortholary O, Dromer F Antimicrob Agents Chemother. 2004; 48(3):970-8.
PMID: 14982791 PMC: 353155. DOI: 10.1128/AAC.48.3.970-978.2004.